The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules

Abstract

The Food and Drug Administration approved 59 new drugs (42 New Chemical Entities and 17 Biologics) during 2018. This number breaks the previous record of 53 approved by the same organization in 1996. The 17 new biologics approved in 2018 also represent an important milestone for this kind of drug and they clearly exceed the 12 approved in 2015 and 2017. Herein, the 59 new drugs of the class of 2018 are analyzed from a strictly chemical perspective. The classification has been carried out on the basis of the chemical structure and includes the following: Biologics (antibodies and enzymes); TIDES (peptides and oligonucleotides) and natural products; drug combinations; and small molecules.

Read full text

Reference:

G de la Torre B, Albericio F. The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules. Molecules. 2019 Feb 23;24(4). pii: E809. doi: 10.3390/molecules24040809. Review. PubMed PMID: 30813407; PubMed Central PMCID: PMC6412490.



Keywords: API; TIDES; antibodies; biologics; chemical entities; drug discovery; fluorine based drugs; natural products; oligonucleotides; peptide; small molecules; The Food and Drug Administration (FDA).

Join for free INPST as a member

The International Natural Product Sciences Taskforce (INPST) maintains up-to-date lists with conferencesgrants and funding opportunitiesjobs and open positions, and journal special issues with relevance for the area of phytochemistry and food chemistry, pharmacology, pharmacognosy research, and natural product science.

Leave a Reply

avatar
  Subscribe  
Notify of